The company also provides consulting services for plant genetic selection, tissue culture technologies for starter plantlets production, SOPs for cultivation and live storage of any plant species services. It sells its products through online stores, such as Amazon and Shopify. As of October 2024, Pharmagreen is developing a specialized form of cannabis oil known as Live Rosin, a highly sought-after cannabis concentrate recognized for its unmatched purity, potency, and rich flavor profile.
Cyborg Score Rationale
Pharmagreen operates as a micro-cap OTC penny stock with minimal market capitalization (~$1.92M as of recent data) and highly speculative revenue projections dependent on multiple unmet regulatory and operational milestones, including cannabis licensing and facility construction. The company faces typical early-stage biotech execution risks with unproven commercialization of ambitious cannabis and nutraceutical initiatives.
Top Insights
Dual-revenue strategy: MaxGenomic nutraceutical supplement line plus speculative cannabis Live Rosin project (announced October 2024) targeting wholesale prices of $40–$100 per gram in U.S. and premium pricing in European markets.
Micro-cap OTC penny stock trading on Pink Sheets with ~663M shares outstanding and ~$1.92M market cap; highly sensitive to small trading volumes and subject to reduced disclosure and reporting standards.
Direct-to-consumer distribution via Amazon and Shopify bypasses traditional retail, enabling lower overhead but requires substantial product/brand awareness in a crowded wellness supplement market.
Cannabis Live Rosin project dependent on securing production/processing licenses, export permits, land leases, and facility funding—outcomes not guaranteed as of October 2024; projected revenues range from $19M–$635M by year 3 based on wholesale pricing assumptions.
Named Competitors
Four Sigmatic — Medicinal mushroom beverage and supplement brand
Nature's Way — Herbal supplement and botanical product manufacturer
GNC — Diversified nutritional supplement retailer and manufacturer
Recent Developments
(October 2024) Announced development of Live Rosin cannabis concentrate project with aggressive revenue projections ($19M–$635M by year 3 depending on per-gram pricing), pending regulatory approvals and facility buildout.
(April 2026) Latest SEC reporting and OTC market data indicate micro-cap status with market cap below $10 million; company continues focus on MaxGenomic nutraceutical commercialization.
Open the full interactive Pharmagreen Biotech Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.